Haemonetics Corp reported $339 million in revenue for the first quarter of fiscal 2027, a 5.6% increase that exceeded expectations, particularly with an adjusted EPS of $1.14, beating the $1.09 consensus estimate. This performance led the company to raise its full-year revenue guidance, signaling confidence to investors.
Key Highlights
- Haemonetics Corp (NYSE: HAE) reported $339 million in revenue for the first quarter of fiscal 2027, demonstrating a 5.6% rise from the previous year.
- These results reflect organic growth rates of 6.0% in Apheresis and 5.9% in MedSurg, showcasing a strong performance across the board.
- Raised Amid Cash Flow Improvement This adjustment reflects the anticipated expansion in both business units.
Haemonetics Corp (NYSE: HAE) reported $339 million in revenue for the first quarter of fiscal 2027, demonstrating a 5.6% rise from the previous year. This solid performance is key as it signifies the company’s successful execution of its growth strategies, particularly in the plasma sector where they have gained market share. Comparatively, this results in a more favorable outlook amidst sector peers like LNTH and MMED, which posted slight declines today.
Strong Operations Drive Growth
These results reflect organic growth rates of 6.0% in Apheresis and 5.9% in MedSurg, showcasing a strong performance across the board. The operating income also increased to $57.5 million, up from $53.9 million the previous year, illustrating improved operational efficiency despite a marginal uptick in operating expenses. With a gross margin of 59.8%, unchanged from the prior year, the company demonstrates effective cost management and pricing strategies.
Guidance
Raised Amid Cash Flow Improvement This adjustment reflects the anticipated expansion in both business units. The first quarter also yielded solid cash flow, with operating activities generating $52 million and free cash flow reaching $39 million, significantly bolstering the company's financial position. As Haemonetics transitions into a more diversified business model, these results support a strong outlook for sustainable growth, attracting keen interest from investors.
Market Performance and Investor Sentiment
The stock’s performance aligns with the company's positive earnings report and raised guidance, appealing to investors looking for growth in the healthcare sector. With the investor conference call scheduled for August 6, market participants will be eager to hear more insights on the company's forward strategy and operational execution.
Conference Call to Provide Further Insights
Investors should look for further commentary during the upcoming conference call today at 8:00 a.m. ET, where management will discuss the quarterly results and outline future expectations. This event presents a key opportunity for investors to gauge the company's trajectory, especially after the notable uptick in guidance. With Haemonetics demonstrating strong operational performance and a proactive approach to expanding revenue streams, the increasing confidence in their fiscal outlook will likely resonate positively in the market.
Peers Moving on This News
- Lantheus Holdings Inc (LNTH) down 0.2%
- MiniMed Group Inc (MMED) down 0.2%
- Merit Medical Systems Inc (MMSI) up 0.4%
Analysis based on the Form 8-K filed 6 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...